|
1
|
Roy R, Zurakowski D, Wischhusen J,
Frauenhoffer C, Hooshmand S, Kulke M and Moses MA: Urinary TIMP-1
and MMP-2 levels detect the presence of pancreatic malignancies. Br
J Cancer. 111:1772–1779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roe JS, Hwang CI, Somerville TDD, Milazzo
JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi
K, et al: Enhancer reprogramming promotes pancreatic cancer
metastasis. Cell. 170:875–888.e20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knudsen ES, O'Reilly EM, Brody JR and
Witkiewicz AK: Genetic diversity of pancreatic ductal
adenocarcinoma and opportunities for precision medicine.
Gastroenterology. 150:48–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang C, Li N, Li Z, Chang A, Chen Y, Zhao
T, Li Y, Wang X, Zhang W, Wang Z, et al: Tumour-derived Interleukin
35 promotes pancreatic ductal adenocarcinoma cell extravasation and
metastasis by inducing ICAM1 expression. Nat Commun. 8:140352017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeSantis CE, Miller KD, Goding Sauer A,
Jemal A and Siegel RL: Cancer statistics for African Americans,
2019. CA Cancer J Clin. 69:211–233. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kotiyal S and Bhattacharya S: Events of
molecular changes in epithelial-mesenchymal transition. Crit Rev
Eukaryot Gene Expr. 26:163–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amawi H, Ashby CR, Samuel T, Peraman R and
Tiwari AK: Polyphenolic nutrients in cancer chemoprevention and
metastasis: Role of the epithelial-to-mesenchymal (EMT) pathway.
Nutrients. 9(pii): E9112017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao XY, Li QQ, Gao YF, Zhou HH, Liu ZQ and
Jin WL: Gap junction as an intercellular glue: Emerging roles in
cancer EMT and metastasis. Cancer Lett. 381:133–137. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petit CS, Barreau F, Besnier L, Gandille
P, Riveau B, Chateau D, Roy M, Berrebi D, Svrcek M, Cardot P, et
al: Requirement of cellular prion protein for intestinal barrier
function and mislocalization in patients with inflammatory bowel
disease. Gastroenterology. 143:122–132.e15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moirangthem A, Bondhopadhyay B, Mukherjee
M, Bandyopadhyay A, Mukherjee N, Konar K, Bhattacharya S and Basu
A: Simultaneous knockdown of uPA and MMP9 can reduce breast cancer
progression by increasing cell-cell adhesion and modulating EMT
genes. Sci Rep. 6:219032016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun F, Zhang Y, Xu L, Li S, Chen X, Zhang
L, Wu Y and Li J: Proteasome inhibitor MG132 enhances
cisplatin-induced apoptosis in osteosarcoma cells and inhibits
tumor growth. Oncol Res. 26:655–664. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crawford LJ and Irvine AE: Targeting the
ubiquitin proteasome system in haematological malignancies. Blood
Rev. 27:297–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan XB, Yang DS, Gao X, Feng J, Shi ZL and
Ye Z: Caspase-8 dependent osteosarcoma cell apoptosis induced by
proteasome inhibitor MG132. Cell Biol Int. 31:1136–1143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gartel AL: A new target for proteasome
inhibitors: FoxM1. Expert Opin Investig Drugs. 19:235–242. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui W, Bai Y, Luo P, Miao L and Cai L:
Preventive and therapeutic effects of MG132 by activating Nrf2-ARE
signaling pathway on oxidative stress-induced cardiovascular and
renal injury. Oxid Med Cell Longev. 2013:3060732013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Albino D, Longoni N, Curti L, Mello-Grand
M, Pinton S, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F,
et al: ESE3/EHF controls epithelial cell differentiation and its
loss leads to prostate tumors with mesenchymal and stem-like
features. Cancer Res. 72:2889–2900. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Longoni N, Kunderfranco P, Pellini S,
Albino D, Mello- Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F,
Chiorino G, et al: Aberrant expression of the neuronal-specific
protein DCDC2 promotes malignant phenotypes and is associated with
prostate cancer progression. Oncogene. 32:2315–2324, 2324.e1-e4.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albino D, Civenni G, Rossi S, Mitra A,
Catapano CV and Carbone GM: The ETS factor ESE3/EHF represses IL-6
preventing STAT3 activation and expansion of the prostate cancer
stem-like compartment. Oncotarget. 7:76756–76768. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Xing J, Cheng R, Shao Y, Li P, Zhu
S and Zhang S: Abnormal localization and tumor suppressor function
of epithelial tissue-specific transcription factor ESE3 in
esophageal squamous cell carcinoma. PLoS One. 10:e01263192015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao T, Jiang W, Wang X, Wang H, Zheng C,
Li Y, Sun Y, Huang C, Han ZB, Yang S, et al: ESE3 inhibits
pancreatic cancer metastasis by upregulating E-cadherin. Cancer
Res. 77:874–885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He M, Qiao Z, Wang Y, Kuai Q, Li C, Wang
Y, Jiang X, Wang X, Li W, He M, et al: chidamide inhibits aerobic
metabolism to induce pancreatic cancer cell growth arrest by
promoting Mcl-1 degradation. PLoS One. 11:e01668962016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seth A and Watson DK: ETS transcription
factors and their emerging roles in human cancer. Eur J Cancer.
41:2462–2478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jain N, Morgan CE, Rife BD, Salemi M and
Tolbert BS: Solution structure of the HIV-1 intron splicing
silencer and its interactions with the UP1 domain of heterogeneous
nuclear ribonucleoprotein (hnRNP) A1. J Biol Chem. 291:2331–2344.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kahlert UD, Joseph JV and Kruyt FAE: EMT-
and MET-related processes in nonepithelial tumors: Importance for
disease progression, prognosis, and therapeutic opportunities. Mol
Oncol. 11:860–877. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim KS, Kim J, Oh N, Kim MY and Park KS:
ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating
cell-cell adhesion-related genes. Biochem Biophys Res Commun.
498:509–515. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang M, Hu C, Tong D, Xiang S, Williams
K, Bai W, Li GM, Bepler G and Zhang X: Ubiquitin-specific peptidase
10 (USP10) deubiquitinates and stabilizes MutS homolog 2 (MSH2) to
regulate cellular sensitivity to DNA damage. J Biol Chem.
291:10783–10791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanchez-Tillo E, Lazaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin-remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matos ML, Lapyckyj L, Rosso M, Besso MJ,
Mencucci MV, Briggiler CI, Giustina S, Furlong LI and Vazquez-Levin
MH: Identification of a novel human E-cadherin splice variant and
assessment of its effects upon EMT-related events. J Cell Physiol.
232:1368–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feldkoren B, Hutchinson R, Rapoport Y,
Mahajan A and Margulis V: Integrin signaling potentiates
transforming growth factor-beta 1 (TGF-β1) dependent
down-regulation of E-cadherin expression-important implications for
epithelial to mesenchymal transition (EMT) in renal cell carcinoma.
Exp Cell Res. 355:57–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
